MAPT and tauopathy: Here, we established a novel peripheral tauopathy model by administering 5 μg of tau-PFFs via tail vein every 2 weeks, aiming to mimic chronic peripheral tau exposure and investigate its effect on systemic inflammation and vascular pathology.